Andrew Baum
Stock Analyst at Citigroup
(2.83)
# 1,653
Out of 4,883 analysts
63
Total ratings
69.77%
Success rate
12.46%
Average return
Main Sectors:
Stocks Rated by Andrew Baum
| Stock | Action | Price Target | Current | Upside | Ratings | Updated | |
|---|---|---|---|---|---|---|---|
| MRK Merck & Co. | Downgrades: Neutral | $115 → $84 | $82.39 | +1.95% | 14 | May 14, 2025 | |
| PFE Pfizer | Maintains: Neutral | $30 → $29 | $25.32 | +14.53% | 10 | Jan 28, 2025 | |
| BMY Bristol-Myers Squibb Company | Maintains: Neutral | $60 → $65 | $47.63 | +36.47% | 11 | Jan 28, 2025 | |
| RPRX Royalty Pharma | Maintains: Buy | $60 → $40 | $36.17 | +10.59% | 2 | Oct 25, 2024 | |
| ABBV AbbVie | Maintains: Buy | $170 → $215 | $190.75 | +12.71% | 10 | Oct 25, 2024 | |
| LLY Eli Lilly and Company | Maintains: Buy | $675 → $895 | $779.28 | +14.85% | 11 | Apr 2, 2024 | |
| ALVO Alvotech | Upgrades: Neutral | $5 → $10 | $8.93 | +11.98% | 3 | Oct 20, 2023 | |
| GSK GSK plc | Downgrades: Neutral | n/a | $38.51 | - | 2 | Jul 5, 2017 |
Merck & Co.
May 14, 2025
Downgrades: Neutral
Price Target: $115 → $84
Current: $82.39
Upside: +1.95%
Pfizer
Jan 28, 2025
Maintains: Neutral
Price Target: $30 → $29
Current: $25.32
Upside: +14.53%
Bristol-Myers Squibb Company
Jan 28, 2025
Maintains: Neutral
Price Target: $60 → $65
Current: $47.63
Upside: +36.47%
Royalty Pharma
Oct 25, 2024
Maintains: Buy
Price Target: $60 → $40
Current: $36.17
Upside: +10.59%
AbbVie
Oct 25, 2024
Maintains: Buy
Price Target: $170 → $215
Current: $190.75
Upside: +12.71%
Eli Lilly and Company
Apr 2, 2024
Maintains: Buy
Price Target: $675 → $895
Current: $779.28
Upside: +14.85%
Alvotech
Oct 20, 2023
Upgrades: Neutral
Price Target: $5 → $10
Current: $8.93
Upside: +11.98%
GSK plc
Jul 5, 2017
Downgrades: Neutral
Price Target: n/a
Current: $38.51
Upside: -